The patent office has allowed a new patent that covers Avanir's (AVNR -0.3%) Nuedexta treatment...

|About: Avanir Pharmaceuticals, Inc (AVNR)|By:, SA News Editor

The patent office has allowed a new patent that covers Avanir's (AVNR -0.3%) Nuedexta treatment for pseudobulbar affect, which is when people have sudden outbursts of involuntary crying or laughing for no apparent reason. The ruling further expands the IP portfolio for Avanir's lead commercial asset. (PR)